CAS 2265899-50-9

ORN0829

CAS: 2265899-49-6, 2265899-50-9

ORN0829 is a novel, orally active, potent, and selective antagonist of serotonin 5-HT2A receptors. ORN0829 has been shown to inhibit the growth of human cancer cells in vitro and in vivo with a side-effect profile that is significantly less than other 5-HT2A antagonists currently in clinical development. ORN0829 also inhibits the binding of serotonin to 5-HT2A receptors and blocks the downstream signaling pathways of phospholipase C, protein kinase C, and mitogen-activated protein kinases.
ORN0829 has an onset latency time of about 1 hour and its pharmacokinetic properties have been evaluated in both mice and rats. In these studies, ORN0829 was found to be well tolerated with no observed adverse effects.

Fórmula: C₂₃H₂₂FN₇O₂

Pureza: Min. 95%

Peso molecular: 447.47 g/mol

Ref: 3D-BO177707

ORN-0829 hydrate

CAS: 2265899-50-9

ORN-0829 hydrate is a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.

Fórmula: C₉₂H₉₀F₄N₂₈O₉

Cor e Forma: Solid

Peso molecular: 1807.91

Ref: TM-T69715